Orphan Star Therapeutics
ANYC-based biopharmaceutical company
About Orphan Star Therapeutics
Orphan Star Therapeutics, LLC is a biopharmaceutical company founded in 2017 by Dr. Nick France, who also serves as the CEO. The company operates out of New York City and is dedicated to creating treatments for rare diseases. Specifically, their focus is on rare genetic and neurometabolic diseases, with Canavan Disease and GluT1 deficiency being key areas of interest. Canavan Disease is a severe genetic neurodegenerative disorder that typically results in fatality within the first decade of a patient's life.
The company's business model revolves around advancing an early-stage pipeline of drug candidates. In September 2018, Orphan Star Therapeutics announced it had secured a $20 million commitment from a commercial pharmaceutical partner to fund these efforts. This capital is intended to advance their pipeline and to acquire promising clinical-stage drug candidates through strategic partnerships with industry and academic institutions. The company aims to expedite the development of targeted treatments that address the root cause of these serious rare disorders.
The company's strategy involves building a portfolio of early-stage drug candidates for these rare conditions. While the full product pipeline has not been publicly disclosed, the initial focus on Canavan Disease highlights their commitment to addressing significant unmet medical needs. To support its mission, Orphan Star has assembled a team of experienced professionals and a Scientific Advisory Board with experts in Canavan disease and gene therapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 2.0/100
- Industry
- Health, Kids
- Sector
- Biotechnology, Hard Tech
- Business model
- Manufacturing
- Client focus
- B2C
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2018 | $20M | $80M | Undisclosed | — |
Growth signals
Latest recorded traffic for Orphan Star Therapeutics is 50 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Orphan Star Therapeutics in the New York City ecosystem
The Orphan Star Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Orphan Star Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Orphan Star Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








